Evotec’s Tightrope Walk: Cost Cuts, a Cash Infusion, and the Threat of Share Dilution
26.05.2026 - 15:40:55 | boerse-global.de
Evotec’s stock is stuck in a rut near the €5 mark, having clawed back about 21% from its 52-week trough of €4.14 set in mid-March. At €5.01 on Tuesday, the shares remain almost 40% below the €8.32 peak touched in May last year. Technical indicators offer little comfort: the 50-day moving average sits at €4.86, the 200-day average at €5.67, and the relative strength index of 60 suggests a modest recovery but no breakout.
The company’s first-quarter numbers, released in May, explain the market’s caution. Revenue slid 21.7% to €156.6 million, weighed down by a tough comparison with the prior year’s Sandoz licence sale and one-off restructuring charges of €75 million. The adjusted EBITDA loss came in at €21.9 million, while the net loss ballooned to €121.9 million. Management points to currency headwinds and sluggish business segments, but the headline figures have left investors wary.
Much now hinges on the Horizon transformation programme, a deep cost-cutting drive that aims to shrink Evotec’s global footprint from 14 sites to 10 and shed around 800 jobs. Consultations with European works councils are expected to conclude by mid-2026, with initial headcount reductions starting in the third quarter. The company targets structural savings of roughly €75 million per year by the end of 2027. That’s a slow squeeze, and the market is watching for signs that the operational uplift is actually materialising.
A timely cash injection should help bridge the gap. Evotec expects to receive around $100 million in gross proceeds from the sale of its Tubulis stake to Gilead, with the payment due in the second quarter of 2026. That liquidity buffer takes some pressure off the balance sheet while management works through the restructuring.
Should investors sell immediately? Or is it worth buying Evotec?
On the governance front, the upcoming annual general meeting will put a performance share plan to a shareholder vote. The proposal creates conditional capital to issue equity awards to the board, subsidiary management, and selected executives. The split is precise: 35% of the awards go to the board, 5% to leaders of affiliated companies, and 60% to senior managers. Each award entitles the holder to a maximum of two shares. For existing shareholders, the risk is dilution if Evotec’s operational recovery fails to keep pace with the new shares hitting the market.
Beyond the numbers, the pipeline is delivering. Evotec nominated a preclinical development candidate under its dermatology alliance with Almirall, achieving the milestone from initial lead compounds in just two years – below the industry benchmark. The programme could unlock up to €230 million in success-based milestones. Separately, the company secured fresh funding from the Gates Foundation for tuberculosis research.
A structural tailwind arrives in June when Evotec rejoins the MDAX index. The promotion should raise visibility among institutional investors and could draw passive inflows as index-tracking funds adjust their holdings.
Evotec at a turning point? This analysis reveals what investors need to know now.
Evotec’s full-year guidance remains unchanged: revenue between €700 million and €780 million, with adjusted EBITDA ranging from break-even to €40 million. The turnaround is expected to gain traction in the second half. With a new finance chief, Claire Hinshelwood – a 30-year veteran previously at BMI Group – now in place since May, the management bench has been refreshed. But the stock’s fate rests on whether Horizon’s cost cuts and the Gilead cash can buy enough time for the pipeline to deliver. For now, the shares are caught between recovery hopes and the threat of dilution, and the next few months will test investors’ patience.
Ad
Evotec Stock: New Analysis - 26 May
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
